MediWound Ltd. (MDWD): Financial results for Q2 2026
MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it
How this was made
The 30-second read
Why it matters
The earnings release shows declining revenue and widening losses, but confirms full‑year guidance and new commercial agreements, suggesting mixed short‑term and long‑term implications.
Market read
The release provides fresh earnings data for a micro‑cap biotech, likely prompting short‑term price pressure but offering upside potential from pipeline milestones.
What to watch
Phase III EscharEx trial enrollment and BARDA contract may drive longer‑term upside despite near‑term revenue dip.
Background
MediWound Ltd., a Nasdaq‑listed biotech, filed its Q2 2026 earnings via Form 6‑K, highlighting trial updates and a BARDA partnership.
Ticker impact
Q2 2026 revenue was $3.1 million and full‑year guidance of $24‑26 million was reaffirmed.
Potential short‑term price decline as results fall short of prior quarter.
Revenue down 45% YoY and net loss widening suggest pressure; guidance unchanged may limit upside.
Market effects
Biotech/health‑care sector may see modest pressure as small‑cap earnings miss expectations.
Limited to U.S. and Israeli markets where MediWound operates.
Low global impact; primarily affects niche investors in biotech.
Counterpoint
Guidance reaffirmation could support a bounce if investors focus on pipeline progress rather than short‑term miss.
Key entities
- companyMediWound Ltd.
Nasdaq‑listed biotech reporting Q2 2026 results.
- partnerVericel
Partnered with MediWound under a BARDA contract for NexoBrid.
